CASSANDRA Phase 3 Trial Shows PAXG Superior to mFOLFIRINOX in Preoperative Pancreatic Cancer Treatment
Key Insights
The CASSANDRA phase 3 trial demonstrated that preoperative PAXG (search) chemotherapy significantly improved event-free survival compared to mFOLFIRINOX (search) in resectable and borderline resectable pancreatic cancer (search) patients.
PAXG (search) achieved a median event-free survival of 16.0 months versus 10.2 months with mFOLFIRINOX (search), with three-year event-free survival rates of 33% versus 13% respectively.
The four-drug PAXG (search) regimen showed superior disease control rates, stronger biomarker responses, and more favorable pathological downstaging without increased severe toxicity.
The CASSANDRA phase 3 trial has established a new benchmark in pancreatic cancer (search) treatment, demonstrating that the four-drug PAXG (search) regimen significantly outperforms modified FOLFIRINOX (mFOLFIRINOX (search)) in the preoperative setting for resectable and borderline resectable pancreatic ductal adenocarcinoma (search) (PDAC (search)). The results, published in The Lancet Oncology on November 20, 2025, represent the first head-to-head comparison showing clear superiority of one intensive chemotherapy regimen over another in early-stage pancreatic cancer.
Trial Design and Patient Population
CASSANDRA was a randomized, open-label, multicenter phase 3 study conducted across 17 Italian academic hospitals. The trial enrolled 260 patients aged 18-75 years with histologically confirmed stage I-III PDAC (search) classified as resectable or borderline resectable based on NCCN criteria. Patients with biological high-risk features, including CA19-9 (search) ≥500 IU/mL, were eligible for inclusion.
Participants were randomized 1:1 to receive four months of either PAXG (search) (cisplatin, nab-paclitaxel, capecitabine, gemcitabine) or mFOLFIRINOX (search) prior to planned surgery. The primary endpoint was event-free survival (EFS), defined as the first occurrence of radiologic progression, recurrence, unresectability, intra-operative metastases, sustained CA19-9 (search) increase, or death.
Superior Efficacy Outcomes
After a median follow-up of 28.5 months, PAXG (search) demonstrated significant superiority across multiple efficacy measures. The median event-free survival reached 16.0 months with PAXG compared to 10.2 months with mFOLFIRINOX (search) (HR 0.63; p=0.0018). The survival benefit was sustained over time, with one-year EFS rates of 61% versus 45% and three-year EFS rates of 33% versus 13%, respectively.
The efficacy advantage extended beyond survival metrics. PAXG (search) achieved higher disease control rates (98% vs 91%) and stronger CA19-9 (search) responses (88% vs 64%). Pathological assessment revealed more favorable outcomes with PAXG, including a higher proportion of early pathological stages (IA-IB: 35% vs 23%) and more node-negative resections (36% vs 23%). Notably, fewer patients in the PAXG arm experienced intra-operative or early postoperative metastases (5% vs 12%).
Safety and Tolerability Profile
Both regimens demonstrated manageable safety profiles in high-volume centers, with severe toxicities occurring in 66% of PAXG (search) patients and 61% of those receiving mFOLFIRINOX (search). While neutropenia was more common with PAXG, this did not translate into increased febrile neutropenia or infections.
The toxicity patterns differed between regimens. mFOLFIRINOX (search) produced more gastrointestinal and neurologic toxicity, including higher rates of nausea, diarrhea, neuropathy, paraesthesia, mucositis, and liver enzyme elevation. The only treatment-related death from sepsis occurred in the mFOLFIRINOX arm, highlighting PAXG (search)'s more favorable safety profile.
Quality of Life Assessment
Quality-of-life evaluations revealed important differences between treatments. More patients in the mFOLFIRINOX (search) arm were unable to complete follow-up assessments due to early disease progression or toxicity, reflecting lower disease control. While both regimens produced expected declines in various quality-of-life domains, PAXG (search) was associated with a more stable trajectory during neoadjuvant therapy.
Clinical Implications
Michele Reni, the trial's lead investigator, emphasized the significance of these findings for clinical practice. The results support preoperative PAXG (search) as a new standard option in resectable and borderline resectable PDAC (search) and establish it as the preferred comparator for future neoadjuvant trials.
Catia Carconi, Research Scholar at The Netherlands Cancer Institute and co-author, highlighted the trial's unique funding model, noting that "CASSANDRA was entirely funded by patient associations, a powerful example of what independent research and community commitment can achieve."
While overall survival data remain immature, early results favor PAXG (search) with a median overall survival of 32.1 versus 26.4 months. The consistent benefit across resectable and borderline resectable subgroups suggests broad applicability of these findings to the target patient population.
The CASSANDRA trial represents a paradigm shift in pancreatic cancer (search) treatment, providing the first definitive evidence that one intensive chemotherapy regimen can meaningfully outperform another in the preoperative setting. These findings are expected to influence treatment guidelines and reshape the standard of care for early-stage pancreatic cancer patients.